CoraLite® Plus 488-conjugated PRAME Monoclonal antibody

• Featured Product
• KD/KO Validated

PRAME Monoclonal Antibody for IF/ICC

Host / Isotype

Mouse / IgG2b

Reactivity

Human, mouse, rat

Applications

IF/ICC

Conjugate

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

1E9G9

Cat no : CL488-68097

Synonyms

MAPE, OIP 4, OIP4, Opa interacting protein 4, PRAME

---

Validation Data Gallery

• 

  IF Staining of HaCaT using CL488-68097

  Immunofluorescent analysis of (4% PFA) fixed HaCaT cells using CoraLite® Plus 488 PRAME antibody (CL488-68097, Clone: 1E9G9 ) at dilution of 1:100, CL594-phalloidin (red).

---

Tested Applications

• Positive IF/ICC detected in: HaCaT cells

Recommended dilution

• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

CL488-68097 targets PRAME in IF/ICC applications and shows reactivity with Human, mouse, rat samples.

• Tested Reactivity: Human, mouse, rat
• Host / Isotype: Mouse / IgG2b
• Class: Monoclonal
• Type: Antibody
• Immunogen: PRAME fusion protein Ag1906
• Full Name: preferentially expressed antigen in melanoma
• Calculated Molecular Weight: 509 aa, 58 kDa
• Observed Molecular Weight: 50 kDa
• GenBank Accession Number: BC014074
• Gene Symbol: PRAME
• Gene ID (NCBI): 23532
• Conjugate: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 493 nm / 522 nm
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.